Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Dušan Milanović"'
Autor:
Marianne Schmucker, Hannah Lorenz, Anca-Ligia Grosu, Horst Urbach, Carsten Nieder, Oliver Oehlke, Angelika Bilger, Dušan Milanović, Astrid Weyerbrock
Publikováno v:
Clinical Neurology and Neurosurgery. 142:81-86
Objectives The goal of this study is to evaluate the role of stereotactic fractionated radiotherapy (SFRT) in patients with one to three brain metastases after surgical resection. Methods and materials We performed a retrospective single-institutiona
Autor:
Nađa Kurtović-Folić, Božidar Stojanović, Dušan Milanović, Vladimir Macura, Vera Mihaljević, Dijana Milašinović-Marić, Miodrag Ferencak, Borislav Stojkov, Zlata Vuksanović-Macura, Jovanka Đorđević-Ciganović, Jasminka Cvejić
Publikováno v:
Arhitektura i urbanizam
Урбанистичке иновације које су се појавиле у Генералном плану Београда, који је Скупштина града Београда усвојила септембра 2003. год., пр
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3613be2e7f0b891cb8eedbd9c06634b1
https://hdl.handle.net/21.15107/rcub_dais_7035
https://hdl.handle.net/21.15107/rcub_dais_7035
Autor:
Nicole Wiedenmann, Angelika Bilger, Philipp T. Meyer, Gabriele Niedermann, Anca-L. Grosu, Dušan Milanović, Martin-Immanuel Bittner, Wolfgang A. Weber, Elke Firat
Publikováno v:
Strahlentherapie und Onkologie. 190:957-961
Treatment of recurrent glioblastoma (rGBM) remains an unsolved clinical problem. Reirradiation (re-RT) can be used to treat some patients with rGBM, but as a monotherapy it has only limited efficacy. Chloroquine (CQ) is an anti-malaria and immunomodu
Autor:
Angelika Bilger, Carsten Nieder, R. Wiehle, Oliver Oehlke, Anca-Ligia Grosu, Florian Frenzel, V. Prokic, Dušan Milanović
Publikováno v:
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, Vol 7, Iss, Pp 55-61 (2017)
Clinical and Translational Radiation Oncology, Vol 7, Iss, Pp 55-61 (2017)
Highlights • LINAC-based frameless radiosurgery shows favorable local control. • 18–20 Gy were delivered as single fraction. • No treatment related side effects ≥grade 2 were observed. • SRS and deferred WBRT remain salvage therapies for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c02a9372ecb335ab3f6268a76606eaca
https://hdl.handle.net/10037/13252
https://hdl.handle.net/10037/13252
Autor:
Oliver Oehlke, Marianne Schmucker, Angelika Bilger, F. Frenzel, R. Wiehle, Anca L. Grosu, Carsten Nieder, Dušan Milanović
Publikováno v:
Neuro-Oncology. 19:iii106-iii106
Introduction: Stereotactic radiosurgery (SRS) has been increasingly advocated for 1-3 small brain metastases. Goal of this study was to evaluate the clinical results in patients with brain metastases treated with SRS using a thermoplastic mask non-in
Publikováno v:
Anticancer research. 34(4)
13-cis-retinoic acid (RA) and thalidomide have shown a synergistic anti-proliferative effect on U343 glioblastoma (GBM) cells. In the present study, we test if their combined treatment might enhance the radiosensitivity of these cells.The radiosensit
Publikováno v:
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. 189(10)
For some patients with recurrent, unresectable, and previously irradiated head and neck squamous cell carcinoma (HNSCC), reirradiation (re-RT) may be a curative option. Chemotherapy with epidermal growth factor receptor (EGFR) inhibition is establish
Publikováno v:
Radiation Oncology (London, England)
Background and purpose Heat shock Protein 90 (Hsp90) is a molecular chaperone that folds, stabilizes, and functionally regulates many cellular proteins involved in oncogenic signaling and in the regulation of radiosensitivity. It is upregulated in re
Autor:
Martin Béhé, Anca L. Grosu, Gabriele Niedermann, Wolfgang Weber, Dušan Milanović, Friederike Braun
Publikováno v:
BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 242 (2012)
BMC Cancer, Vol 12, Iss 1, p 242 (2012)
Background One of the most important biological characteristics of Glioblastoma multiforme (GBM) is high vascular density. Vadimezan (ASA404, DMXAA) belongs to the class of small molecule vascular disrupting agents (VDA) that cause disruption of esta